OSTX_OUT_1 [2025-04-29 04:53:41 -0400] 5351 Bytes | 1412 tokens | Cum: 1412 tkns (17.65% of 8k)
==========================================================================

Logic dictates we seek momentum where momentum lives. At 4:53 AM on Tue Apr 29, 2025, OS Therapies Incorporated (OSTX) rises from $1.60 to $1.83. Fascinating. Let us analyze without emotion, but with purpose.

--- COMPANY PROFILE ---
Company: OS Therapies Incorporated (OSTX)
IPO: 2024-08-01 (9 Months Ago)
Market Cap: $28,947,852
Shares Outstanding: 21,770,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XASE
Description: OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the significant need for new treatments in cancers of the bone in children and young adults.

Here’s a list of headlines for OS Therapies Incorporated:

Apr-22-25 07:40AM - OS Therapies FDA Meeting Request Granted
Apr-14-25 10:15AM - With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz
Apr-10-25 07:42AM - OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans
Apr-09-25 07:40AM - OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals
Apr-07-25 06:00AM - OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma
Apr-02-25 07:40AM - OS Therapies to Host Analyst Day at NYSE on April 7, 2025
Mar-31-25 04:30PM - OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update
Mar-31-25 04:30PM 07:40AM - OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma
Mar-25-25 07:40AM - OS Therapies OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers
Mar-23-25 08:49AM - OS Therapies (OSTX): Among the Penny Stocks With Huge Upside Potential According to Analysts
Mar-21-25 07:40AM - OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference
Mar-13-25 07:40AM - OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference
Mar-11-25 07:40AM - OS Therapies Schedules United Kingdoms Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma
Feb-28-25 09:00AM - Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Feb-26-25 04:01PM - Join OS Therapies Exclusive Live Investor Webinar and Q&A Session on February 27
Feb-24-25 07:25AM - OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms
Feb-20-25 05:00AM - OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2
Feb-14-25 01:51PM - Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer
Feb-14-25 01:51PM 07:36AM - OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
Feb-04-25 07:33AM - OS Therapies Provides Corporate Update
Feb-03-25 08:30AM - RedChip Launches RedChat: Revolutionary AI Chatbot for Small-Cap Stock Analysis
Jan-30-25 09:35AM - OS Therapies to acquire listeria programs from Ayala Pharmaceuticals

Prior AI Reports for OSTX:
1. 2025-04-02 – Score: 15 – Target: 1.5484 – Highs: 1.5600 / 1.7999 / 1.56
companys-negative-trend-signals-caution-for-investors

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for OS Therapies Incorporated (OSTX).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

OSTX_OUT_3 [2025-04-29 04:53:42 -0400] 850 Bytes | 250 tokens | Cum: 1664 tkns (20.80% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-14T14:10:00Z - With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz - CEL-SCI (AMEX:CVM), Actiniu...
A2 - 2025-04-14T14:17:41Z - With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz - Weekly Voice...
A3 - 2025-04-14T14:18:00Z - Equity Insider: With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz...
A4 - 2025-04-12T09:55:29Z - OS Therapies Inc (NYSE:OSTX) Major Shareholder Sells $67,516.20 in Stock...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

OSTX_OUT_5 [2025-04-29 04:53:43 -0400] 1182 Bytes | 320 tokens | Cum: 1986 tkns (24.82% of 8k)
==========================================================================

Showing A1 (chunk 1 of 17): A1:
**With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz - CEL-SCI (AMEX:CVM), Actinium Pharma (AMEX:ATNM)**Date: 2025-04-14Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/pressreleases/25/04/n44790514/with-young-adult-cancer-on-the-rise-new-therapies-spark-investor-buzzEquity Insider News Commentary

Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC, April 14, 2025 /PRNewswire/ -- Equity Insider News Commentary - Routine medical appointments or cancer screenings -- critical for catching the disease in earlier, more treatable stages -- has dropped to just over 50% of the population. At the same time, doctors are raising alarm bells over a noticeable increase in cancer diagnoses among younger adults, especially women. With proposed funding cuts to the NIH now on the table and new estimates suggesting that d

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

OSTX_OUT_7 [2025-04-29 04:53:44 -0400] 1182 Bytes | 292 tokens | Cum: 2280 tkns (28.50% of 8k)
==========================================================================

Showing A1 (chunk 2 of 17): rug tariffs could add $10,000 or more to treatment costs, the path forward may rely less on government programs and more on private-sector breakthroughs. So far in 2025, several oncology innovators have stepped forward with meaningful updates, including Oncolytics Biotech Inc. ONCY ONC, CEL-SCI Corporation (NYSE-American: CVM), OS Therapies Incorporated (NYSE-American: OSTX), BeiGene, Ltd. ONC, and Actinium Pharmaceuticals, Inc. (NYSE-American: ATNM).

Forecasts show cancer's global footprint expanding sharply, with annual case counts expected to rise 20% by 2030 and swell by 75% by mid-century, according to Statista. Meanwhile, Precedence Research projects the global immunotherapy drugs market will reach nearly US$1.2 trillion by 2033, driven by an 18% compound annual growth rate.

Oncolytics Biotech Inc. ONCY ONC recently turned heads after securing a new share purchase agreement with

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

OSTX_OUT_9 [2025-04-29 04:53:45 -0400] 1182 Bytes | 254 tokens | Cum: 2536 tkns (31.70% of 8k)
==========================================================================

Showing A1 (chunk 3 of 17): Alumni Capital that could provide up to US$20 million in flexible financing, and potentially increase available capital by nearly 45% of the company's valuation at the time of the announcement. The deal gives Oncolytics the right -- but not the obligation -- to raise capital over a 15-month period through equity sales under its own control.

For a clinical-stage company heading toward multiple inflection points, the agreement offers an important advantage: access to cash if and when it's strategically needed. The announcement was met with heightened market interest, driving a notable spike in share price and trading volume on Friday, as investors reacted to the added financial runway and the timing of upcoming trial updates.

The capital agreement reinforces a broader narrative taking shape in 2025. Oncolytics continues to advance pelareorep, its intravenously delivered immunotherapy, wh

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

OSTX_OUT_11 [2025-04-29 04:53:46 -0400] 1182 Bytes | 269 tokens | Cum: 2807 tkns (35.09% of 8k)
==========================================================================

Showing A1 (chunk 4 of 17): ich triggers a systemic immune response against tumors.

Pelareorep is being tested across multiple solid tumor types where outcomes remain poor, including HR-positive HER2-negative metastatic breast cancer, pancreatic ductal adenocarcinoma (PDAC), and advanced anal cancer. All three indications are now being studied in multi-drug combination trials that reflect real-world treatment settings and physician preferences.

"With multiple clinical trials surpassing expectations in 2024, 2025 is shaping up to be a defining year for Oncolytics," said Wayne Pisano, Chair of Oncolytics' Board of Directors and Interim CEO in a recent update. "Our top priority is HR+/HER2- metastatic breast cancer, in which two randomized trials involving over 100 patients have shown substantial clinical benefit for patients receiving pelareorep and paclitaxel compared to paclitaxel monotherapy. We believe that if

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

OSTX_OUT_13 [2025-04-29 04:53:46 -0400] 1182 Bytes | 261 tokens | Cum: 3070 tkns (38.38% of 8k)
==========================================================================

Showing A1 (chunk 5 of 17): we can approximate the benefit we saw in BRACELET-1 in our planned registrational study, the progression-free survival benefit alone would support an accelerated approval submission."

In breast cancer, the company recently completed a randomized Phase 2 trial called BRACELET-1. In this study, patients treated with pelareorep and paclitaxel outperformed those receiving paclitaxel alone, showing a near doubling in progression-free survival. The company has stated that the data support moving ahead with a larger registrational study, expected to begin later this year. If new results mirror those seen in BRACELET-1, Oncolytics may have the foundation to submit for accelerated approval in this indication.

Meanwhile, the company continues to expand its gastrointestinal cancer program. A pancreatic cancer cohort within the GOBLET study is moving toward full enrollment, after clearing safety h

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

OSTX_OUT_15 [2025-04-29 04:53:47 -0400] 1182 Bytes | 278 tokens | Cum: 3350 tkns (41.88% of 8k)
==========================================================================

Showing A1 (chunk 6 of 17): urdles with regulators in Germany. Patients will receive pelareorep alongside a modified FOLFIRINOX chemotherapy regimen -- with or without the checkpoint inhibitor atezolizumab. Interim efficacy results from this arm are expected later in 2025 and may inform the structure of a future registration-enabling trial. Notably, Oncolytics is working with the Pancreatic Cancer Action Network (PanCAN) on this cohort, as they provided a US$5 million grant to fund it.

In advanced anal cancer, pelareorep is being tested with atezolizumab in another GOBLET cohort. Among the first 12 patients, four showed partial responses and one had a complete response lasting over 15 months. Based on these early outcomes -- stronger than what's typically seen from checkpoint inhibitors alone -- the company has expanded the cohort to include an additional 18 patients.

Pelareorep's unique mechanism of action has g

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

OSTX_OUT_17 [2025-04-29 04:53:50 -0400] 1182 Bytes | 298 tokens | Cum: 3650 tkns (45.62% of 8k)
==========================================================================

Showing A1 (chunk 7 of 17): arnered attention from key opinion leaders in immunotherapy. During a recent event hosted by H.C. Wainwright, Profs. Martine Piccart and Alexander Eggermont emphasized pelareorep's ability to turn so-called "cold" tumors "hot," potentially enhancing the effectiveness of checkpoint inhibitors and other cancer therapies in difficult-to-treat cancers like PDAC and HR+/HER2- metastatic breast cancer.

As of the end of Q4 2024, Oncolytics reported $15.9 million in cash on hand, with operations funded into the third quarter of 2025. With late-stage trials being planned, multiple data readouts on the horizon, and a flexible US$20 million equity facility now in place, the company enters Q2 not just with momentum -- but with the financial agility to match it.

CONTINUED... Read this and more news for Oncolytics Biotech at: https://equity-insider.com/2025/03/18/is-oncolytics-biotech-the-markets-mo

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

OSTX_OUT_19 [2025-04-29 04:53:51 -0400] 1182 Bytes | 261 tokens | Cum: 3913 tkns (48.91% of 8k)
==========================================================================

Showing A1 (chunk 8 of 17): st-undervalued-cancer-opportunity/

In other recent industry developments and happenings in the market include:

CEL-SCI Corporation (NYSE-American: CVM) is gaining traction after a study published in Cancer Cell validated its approach to seeking early approval for Multikine, its lead immunotherapy candidate for head and neck cancer.

"The data from both our completed Multikine neoadjuvant Phase 3 study and the study published in Cancer Cell show that newly diagnosed locally advanced head and neck cancer patients who were treated with immune therapies before surgery and had tumor responses, were also likely to have better overall survival," said Geert Kersten, CEO of CEL-SCI. "This is quite logical -- when a person's tumor shrinks in response to immunotherapy treatment before the tumor is removed by surgery -- their survival outcome is expected to be better."

Patients who responded to M

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

OSTX_OUT_21 [2025-04-29 04:53:51 -0400] 1182 Bytes | 248 tokens | Cum: 4163 tkns (52.04% of 8k)
==========================================================================

Showing A1 (chunk 9 of 17): ultikine before surgery had significantly higher survival rates than those who didn't respond. The FDA has approved a 212-patient confirmatory trial to support the company's regulatory path forward.

"We believe that the recent greater availability of peer-reviewed published data specific to neoadjuvant therapy and early tumor response in head and neck cancer supports our development and regulatory efforts," added Kersten.

OS Therapies Incorporated (NYSE-American: OSTX), has completed its acquisition of Advaxis Immunotherapies' listeria-based cancer programs, securing full IP ownership and strengthening its leadership in this emerging therapeutic category.

"We are thrilled to have now consolidated all of the intellectual property for the listeria cancer immunotherapy platform into OS Therapies, positioning us to fully expand it in the years ahead and improve the standard of care across

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

OSTX_OUT_23 [2025-04-29 04:53:52 -0400] 1183 Bytes | 276 tokens | Cum: 4441 tkns (55.51% of 8k)
==========================================================================

Showing A1 (chunk 10 of 17): cancer treatment in the years ahead," said Paul Romness, CEO of OS Therapies. "We now have late-stage, mid-stage and early-stage cancer immunotherapy candidates, a rich pipeline of preclinical cancer immunotherapy candidates and a long IP runway to in order to fully leverage this powerful cancer immunotherapy platform."

The company's pipeline now includes three clinical-stage immunotherapies and eight additional preclinical assets aimed at more than 30 cancer types. Its lead candidate, OST-HER2, is expected to be submitted for FDA accelerated approval by year-end for recurrent, lung-metastatic osteosarcoma. If approved, the company would become eligible for a Priority Review Voucher, currently valued at $150 million.

BeiGene, Ltd. ONC recently received a positive opinion from the European Medicines Agency's CHMP for TEVIMBRA (tislelizumab) in combination with chemotherapy as a first-l

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

OSTX_OUT_25 [2025-04-29 04:53:52 -0400] 1093 Bytes | 293 tokens | Cum: 4736 tkns (59.20% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-15 8-K Item 9.01 Fin Stmnts and Exhibits.

(d) Exhibits.

Exhibit Number Description 4.1 Form of Warrant (incorporated by reference to Exhibit 4.1 to the Curr Report on Form 8-K filed on January 29, 2025). 10.1 Asset Purchase Agrmt, dated as of January 28, 2025, betwe...

S3 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere...

S4 - 2025-03-31 8-K Item 2.02. Results of Oper and Fin Cond.

On March 31, 2025, OS Therapies Incorporated, a clinical-stage cancer immunotherapy and ADC biotechnology company, issued a press release announcing its financial results for the quarter and year ended December 31, 2024....

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

OSTX_OUT_27 [2025-04-29 04:53:53 -0400] 1181 Bytes | 319 tokens | Cum: 5057 tkns (63.21% of 8k)
==========================================================================

Showing S1 (chunk 1 of 2): S1:
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number Description 4.1 Form of Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed on January 29, 2025). 10.1 Asset Purchase Agreement, dated as of January 28, 2025, between OS Therapies Incorporated and Ayala Pharmaceuticals, Inc. incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on January 29, 2025).* 10.2 Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on January 29, 2025). 99.1 Press release, dated April 9, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

* Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplemental copies of any of the omi

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

OSTX_OUT_29 [2025-04-29 04:53:53 -0400] 337 Bytes | 95 tokens | Cum: 5154 tkns (64.42% of 8k)
==========================================================================

Showing S1 (chunk 2 of 2): tted schedules or exhibits upon request by the SEC....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

OSTX_OUT_31 [2025-04-29 04:54:00 -0400] 6459 Bytes | 1680 tokens | Cum: 6836 tkns (85.45% of 8k)
==========================================================================

This is our set of metrics for OS Therapies Incorporated.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+-----------------------+
| Volume: 524,845 | Perf Month: 12.35% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+-----------------------+
| Avg Volume: 842.91K | Perf Quarter: -27.20% | Short Float: 2.31% | ROE: - |
+---------------------+-----------------------+------------------------+-----------------------+
| Rel Volume: 0.63 | Index: - | Short Ratio: 0.43 | ROI: -1341.51% |
+---------------------+-----------------------+------------------------+-----------------------+
| RSI (14): 61.96 | Market Cap: 43.37M | Short Interest: 0.36M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+-----------------------+
| ATR (14): 0.19 | Shs Outstand: 20.87M | Beta: - | EPS Surprise: -32.59% |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA20: 24.61% | Shs Float: 15.66M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA50: 14.61% | Inst Own: 0.61% | Sales past 5Y: 0.00% | Earnings: Mar 31 AMC |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA200: -33.49% | Insider Own: 34.28% | Employees: 4 | |
+---------------------+-----------------------+------------------------+-----------------------+
| Perf Week: 22.15% | Insider Trans: -2.12% | Debt/Eq: - | |
+---------------------+-----------------------+------------------------+-----------------------+

The next section covers any insider trading by OS Therapies Incorporated officers or majority shareholders (if available).

Inside Trans: OS Therapies Inc (OSTX) by Auerbach Shalom (Unknown Title) on 2025-04-09
- Common Stock, par value $0.001 per share: 50012 shares at $1.353 (I)
- Common Stock, par value $0.001 per share: 10000 shares at $1.39 (I)

Inside Trans: OS Therapies Inc (OSTX) by Romness Paul A. (President and CEO) on 2025-02-28
- Common Stock, par value $0.001 per share: 225000 shares at $0 (D)

Inside Trans: OS Therapies Inc (OSTX) by Auerbach Shalom (Unknown Title) on 2025-02-27
- Common Stock, par value $0.001 per share: 225000 shares at $1.64 (I) Footnote: Forfeiture of shares of Common Stock that were held in escrow pursuant to a Transfer Agreement that Einodmil entered into on May 13, 2024. The shares of Common Stock were forfeited pursuant to the terms and conditions of the Transfer Agreement.

Inside Trans: OS Therapies Inc (OSTX) by Auerbach Shalom (Unknown Title) on 2025-02-14
- Common Stock, par value $0.001 per share: 100000 shares at $2.843 (I)

No transactions recorded.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: {'value': -2875232.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.82
Average Volume: 195668.15
30-Day High: 1.82
30-Day Low: 1.12

[Detailed Financials: Q3 2024]
- Total Assets: $1,977,264.00
- Total Liabilities: $2,684,391.00
- Total Equity: $-707,127.00
- Current Assets: $1,970,604.00
- Current Liabilities: $2,584,391.00

[Income Statement: Q3 2024]
- Revenue: N/A
- Net Income: $-2,875,232.00
- Gross Profit: N/A
- Operating Income: $-2,437,393.00
- Earnings Per Share (EPS): -0.18

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $0.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of OS Therapies Incorporated (OSTX).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about OS Therapies Incorporated.

2) MARKET_SCORE[]
This conversation was initiated because OSTX is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for OSTX.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, OSTX could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect OSTX to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of OS Therapies Incorporated.

11) ETHICAL_RATING[]
Rate OS Therapies Incorporated’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of OS Therapies Incorporated.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

OSTX_IN_33 [2025-04-29 04:54:01 -0400] 126 Bytes | 29 tokens | Cum: 7069 tkns (88.36% of 8k)
==========================================================================

====================================
[2025-04-29 04:54:01] # Analysis Completed
Elapsed Time: 20.66 seconds